Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Location
Brisbane, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 24 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 915% % 17%
Quick Ratio 11% %
Debt-to-equity 13% % -12%
Return On Equity -23% % -1.9%
Return On Assets -21% % -3.5%
Operating Margin -81% % 51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 103,297,691 shares 1.9%
Common Stock, Shares, Outstanding 102,982,700 shares 1.8%
Entity Public Float $567,000,000 USD -42%
Common Stock, Value, Issued $10,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 103,205,703 shares 11%
Weighted Average Number of Shares Outstanding, Diluted 103,205,703 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $158,182,000 USD 21%
Research and Development Expense $148,135,000 USD -35%
General and Administrative Expense $120,587,000 USD 4.4%
Operating Income (Loss) $127,750,000 USD 41%
Nonoperating Income (Expense) $18,452,000 USD -86%
Income Tax Expense (Benefit) $1,976,000 USD -128%
Net Income (Loss) Attributable to Parent $107,322,000 USD -12%
Earnings Per Share, Basic -1.04 USD/shares -2%
Earnings Per Share, Diluted -1.04 USD/shares -2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $197,078,000 USD 58%
Inventory, Net $6,326,000 USD 90%
Assets, Current $485,099,000 USD -14%
Property, Plant and Equipment, Net $2,136,000 USD -6.5%
Operating Lease, Right-of-Use Asset $2,342,000 USD -3.3%
Assets $507,827,000 USD -13%
Accounts Payable, Current $3,733,000 USD 14%
Liabilities, Current $60,522,000 USD -18%
Operating Lease, Liability, Noncurrent $2,619,000 USD 1%
Other Liabilities, Noncurrent $484,000 USD -36%
Liabilities $66,665,000 USD -17%
Accumulated Other Comprehensive Income (Loss), Net of Tax $65,000 USD -23%
Retained Earnings (Accumulated Deficit) $661,403,000 USD -19%
Stockholders' Equity Attributable to Parent $441,162,000 USD -12%
Liabilities and Equity $507,827,000 USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $58,997,000 USD -19%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $32,613,000 USD -137%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 102,982,700 shares 1.8%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $197,078,000 USD 58%
Deferred Tax Assets, Valuation Allowance $186,143,000 USD 20%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross $188,041,000 USD 20%
Operating Lease, Liability $2,793,000 USD 7.3%
Payments to Acquire Property, Plant, and Equipment $317,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $107,341,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid $4,262,000 USD -2.6%
Operating Lease, Liability, Current $174,000 USD 1640%
Lessee, Operating Lease, Liability, to be Paid, Year Two $543,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year One $527,000 USD 51%
Operating Lease, Weighted Average Discount Rate, Percent 0.129 pure 0%
Deferred Income Tax Expense (Benefit) $900,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,469,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $501,000 USD 13%
Unrecognized Tax Benefits $9,054,000 USD 42%
Lessee, Operating Lease, Liability, to be Paid, Year Four $711,000 USD 55%
Operating Lease, Payments $4,400,000 USD
Additional Paid in Capital $1,102,490,000 USD 4.3%
Amortization of Intangible Assets $3,110,000 USD 112%
Depreciation, Depletion and Amortization $94,000 USD 309%
Share-based Payment Arrangement, Expense $44,388,000 USD -8%